ZYME vs. ALVO, IMVT, VKTX, RYTM, SRRK, CRNX, MRUS, PTGX, APLS, and BHVN
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Alvotech (ALVO), Immunovant (IMVT), Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.
Zymeworks vs.
Alvotech (NASDAQ:ALVO) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.
Alvotech presently has a consensus price target of $18.00, indicating a potential upside of 54.37%. Zymeworks has a consensus price target of $21.00, indicating a potential upside of 64.06%. Given Zymeworks' higher probable upside, analysts plainly believe Zymeworks is more favorable than Alvotech.
In the previous week, Zymeworks had 8 more articles in the media than Alvotech. MarketBeat recorded 22 mentions for Zymeworks and 14 mentions for Alvotech. Zymeworks' average media sentiment score of 1.60 beat Alvotech's score of 0.58 indicating that Zymeworks is being referred to more favorably in the news media.
Zymeworks received 287 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 67.74% of users gave Zymeworks an outperform vote while only 50.00% of users gave Alvotech an outperform vote.
Alvotech has a net margin of -123.47% compared to Zymeworks' net margin of -182.75%. Alvotech's return on equity of 0.00% beat Zymeworks' return on equity.
Zymeworks has lower revenue, but higher earnings than Alvotech. Zymeworks is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.
Alvotech has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
92.9% of Zymeworks shares are owned by institutional investors. 0.5% of Alvotech shares are owned by company insiders. Comparatively, 1.9% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Zymeworks beats Alvotech on 14 of the 19 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
This page (NYSE:ZYME) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy ZYME Stock Free ZYME Stock Alerts